Cadmium induces renal inflammation by activating the NLRP3 inflammasome through ROS/MAPK/NF-κB pathway in vitro and in vivo

Cadmium (Cd) has been reported to induce kidney damage by triggering oxidative stress and inflammation. The NLR family Pyrin Domain Containing 3 (NLRP3) inflammasome has been implicated a role in the pathogenesis of inflammation. However, the connection between Cd and NLRP3 inflammasome in the development of renal inflammation remains unknown. In this study, in vitro experiments based on the telomerase-immortalized human renal proximal-tubule epithelial cell line (RPTEC/TERT1) were carried out. Results revealed that CdCl2 (2-8 mu M) increased ROS production and activated NLRP3, thereby enhancing secretion of IL-1 beta and IL-18 (P < 0.05). Knock-down of NLRP3 rescued the RPTEC/TERT1 cells from Cd-induced inflammatory damage. Cd activated the MAPK/NF-kappa B signaling pathway in RPTEC/TERT1 cells (P < 0.05). In addition, treatment with N-acetylcysteine (NAC) improved inflammation and blocked the upregulation of the MAPK/NF-kappa B signaling pathway. Pre-treatment with MAPK and NF-kappa B inhibitors also suppressed NLRP3 inflammasome activation (P < 0.05). Moreover, CdCl2 (25-00 mg/L) stimulated the MAPK/NF-kappa B signaling pathway, activated the NLRP3 inflammasome, and increased inflammatory response (P < 0.05) leading to renal injury in rats. Exposure to cadmium elevated serum levels of NLRP3 and IL-1 beta in populations (P < 0.05). Further analysis found that serum NLRP3 and IL-1 beta levels were positively correlated with urine cadmium (UCd) and urine N-acetyl-beta-D-glucosaminidase (UNAG). Overall, Cd induced renal inflammation through the ROS/MAPK/NF-kappa B signaling pathway by activating the NLRP3 inflammasome. Our research thus provides new insights into the molecular mechanism that NLRP3 contributes to Cd-induced kidney damage.

Automated summary

This study reveals that cadmium induces renal inflammation by activating the NLRP3 inflammasome through the ROS/MAPK/NF-kappa B signaling pathway. Knock-down of NLRP3 or treatment with N-acetylcysteine can alleviate inflammation caused by cadmium exposure. Serum levels of NLRP3 and IL-1 beta are positively correlated with urine cadmium and urine N-acetyl-beta-D-glucosaminidase, indicating their potential as biomarkers for cadmium-induced kidney damage.